IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
14 mars 2024 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release...
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
11 mars 2024 07h45 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx...
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
20 févr. 2024 10h50 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to...
IntelGenx Launches Preferred Share Regulation A Offering
20 févr. 2024 07h50 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to...
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
05 févr. 2024 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study...
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
18 déc. 2023 07h15 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license...
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
05 déc. 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced...
IntelGenx Announces Changes to its Board of Directors
04 déc. 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Frank Stegert and Srinivas...
IntelGenx Announces Shareholder Approval of Financing Transactions
28 nov. 2023 16h05 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier...
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
14 nov. 2023 07h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the Swedish Medical Products Agency (“MPA”), the...